Venetoclax - Generic Drug Details

What are the generic drug sources for venetoclax and what is the scope of freedom to operate?

Venetoclax is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Venetoclax has two hundred and sixty-six patent family members in forty-three countries.

One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for venetoclax

International Patents:	266
US Patents:	10
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	678
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for venetoclax
What excipients (inactive ingredients) are in venetoclax?	venetoclax excipients list
DailyMed Link:	venetoclax at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for venetoclax

Constraining patent/regulatory exclusivity:

11,369,599

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for venetoclax

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Princess Maxima Center for Pediatric Oncology	PHASE1
AstraZeneca	PHASE1
Massachusetts General Hospital	EARLY_PHASE1

See all venetoclax clinical trials

Generic filers with tentative approvals for VENETOCLAX

Applicant	Application No.	Strength	Dosage Form
		50MG	TABLET
		100MG	TABLET

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for venetoclax

Drug Class	BCL-2 Inhibitor
Mechanism of Action	P-Glycoprotein Inhibitors
Physiological Effect	Increased Cellular Death

Anatomical Therapeutic Chemical (ATC) Classes for venetoclax

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for VENETOCLAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VENCLEXTA	Tablets	venetoclax	10 mg, 50 mg and 100 mg	208573	2	2020-04-13

US Patents and Regulatory Information for venetoclax

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes	8,722,657			Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No	8,722,657			Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No	10,993,942
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016		RX	Yes	No	10,730,873			Y

EU/EMA Drug Approvals for venetoclax

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH Co. KG	Venclyxto	venetoclax	EMEA/H/C/004106Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.	Authorised	no	no	no	2016-12-04

International Patents for venetoclax

Country	Patent Number	Title	Estimated Expiration
Japan	6038195
Canada	2759182
Japan	6637119
Japan	2015529225	タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法
New Zealand	595708

Supplementary Protection Certificates for venetoclax

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435432	CR 2017 00021	Denmark		PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207
2435432	132017000054735	Italy		PRODUCT NAME: VENETOCLAX(VENCLYXTO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1138, 20161207
2435432	PA2017015,C2435432	Lithuania		PRODUCT NAME: VENETOKLAKSAS; REGISTRATION NO/DATE: EU/1/16/1138 20161205
2435432	C02435432/01	Switzerland		PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66235 08.05.2018
2435432	300873	Netherlands		PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207

Market Dynamics and Financial Trajectory for Venetoclax

Last updated: March 18, 2026

What is Venetoclax and How is it Positioned in the Market?

Venetoclax (brand name Venclexa) is a BCL-2 inhibitor approved for treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). Since its 2016 FDA approval for CLL with 17p deletion, Venetoclax secured a significant market presence owing to its targeted mechanism and oral administration.

Market Size and Revenue Trends

Global Revenue

In 2022, Venetoclax generated approximately $3.1 billion in global sales, representing a compound annual growth rate (CAGR) of around 36% from 2018 when it launched. The drug's revenue comprises initial monotherapy approvals and later expanded indications.

Year	Global Sales (USD Billion)	CAGR (%)
2018	0.6	N/A
2019	1.2	100
2020	1.8	50
2021	2.6	44
2022	3.1	19

Regional Distribution

North America accounts for approximately 70% of sales, driven by widespread adoption post-FDA approvals. Europe holds 20%, with Asia-Pacific comprising the remainder, primarily fueled by emerging markets.

Key Drivers of Market Dynamics

• Expanded Indications: FDA approval in AML (2020) and subsequent trials in multiple myeloma expand the patient pool.
• Line of Therapy Positioning: Venetoclax is used in frontline and relapsed/refractory settings, increasing its adoption.
• Combination Regimens: Incorporation with agents like obinutuzumab and azacitidine enhances efficacy, attracting prescribers.
• Oral Administration: Convenience over traditional chemotherapy increases patient compliance and market appeal.
• Competitive Landscape: Other BCL-2 inhibitors like S55746 face market entry, but Venetoclax remains the market leader due to early approval and established efficacy.

Market Challenges

• Pricing and Reimbursement: High drug costs (>USD 10,000/month) exert pressure on payers.
• Safety Profile: Side effects like tumor lysis syndrome (TLS) require monitoring, affecting prescriber confidence.
• Resistance Development: Mutations in BCL-2 or upregulation of alternative pathways reduce long-term efficacy.
• Regulatory Variability: Differing approvals and guidelines across regions impact sales growth.

Financial Trajectory and Forecasts

Near-term Outlook (2023-2027)

Market analysts project Venetoclax will sustain high growth through 2027, reaching approximately USD 5.8 billion globally. The CAGR may slow to around 20-25% due to market penetration saturation in existing indications but will benefit from new approvals.

Year	Projected Sales (USD Billion)	Notes
2023	3.9	From incremental adoption and pipeline progress
2024	4.4	Expected expansion into additional AML patient subsets
2025	5.0	Possible new indication approvals
2026	5.4	Increased combination therapy adoption
2027	5.8	Market saturation mitigated by pipeline advancements

Long-term Outlook (2028+)

Market growth will depend heavily on:

1. Pipeline Success: Trials in multiple myeloma and other hematological malignancies could open new revenue streams.
2. Pricing Strategies: Negotiations with payers and potential biosimilars or generics influence profit margins.
3. Global Expansion: Entry into emerging markets will expand total revenue but faces regulatory and access hurdles.

Competitive Dynamics

Competitor	Product Status	Market Share (Estimated 2022)	Key Differentiator
AbbVie (Venetoclax)	Approved in multiple indications, established leader	85%	First-to-market, robust clinical data
S55746 (Selinexor)	Not a BCL-2 inhibitor, competes in AML	~5%	Different mechanism, FDA-approved in specific AML subsets
Other biosimilars	Under development	N/A	Price competition, future impact

Regulatory and Policy Influence

• FDA and EMA approvals for additional indications are critical for growth.
• Pricing negotiations with payers in major markets influence revenue.
• Orphan drug designations in some jurisdictions provide incentives for expansion into rare cancers.

Strategic Opportunities and Risks

Opportunities

• Accelerate expansion in AML and multiple myeloma.
• Develop novel combination therapies.
• Enter emerging markets with limited treatment options.

Risks

• Competitive intensity intensifies, reducing market share.
• Safety concerns could limit adoption.
• Cost containment policies could pressure pricing.

Key Takeaways

• Venetoclax remains a leading BCL-2 inhibitor with sustained high growth, primarily driven by expanded indications and combination therapies.
• Revenue growth is expected to slow but continue into the late 2020s, reaching near USD 6 billion globally.
• Market expansion into other hematological malignancies and geographic regions presents valuable opportunities.
• Pricing, safety management, and resistance are ongoing challenges impacting financial trajectories.

FAQs

1. What are the primary indications for Venetoclax?
   Treatment of CLL with 17p deletion, AML, and SLL in combination with other therapies.

2. How does Venetoclax compare to competing drugs?
   It has a first-mover advantage with extensive clinical data and is the market leader among BCL-2 inhibitors.

3. What factors could limit Venetoclax’s market growth?
   High costs, safety concerns, resistance development, and regulatory or reimbursement barriers.

4. Are new indications expected to influence sales?
   Yes, clinical trial results and regulatory approvals in multiple myeloma and other cancers could double the patient population.

5. What is the impact of generics or biosimilars?
   In the long term, biosimilar entry post-patent expiry may reduce prices and margins, though patents extend into the late 2020s.

---

References

[1] Market data and trend analysis based on IQVIA, 2022.
[2] FDA press releases, 2020-2022.
[3] Company financial reports, 2018-2022.
[4] EvaluatePharma, 2022.
[5] European Medicines Agency, 2022.